Therapeutic Asset Ratings
368 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ct048 autologous
Pancreatic Neoplasm
Peking University
P1
C
(36)
Dat-2645
Pancreatic Neoplasm
Danatlas Pharmaceuticals Co., Ltd
P1
C
(36)
Eli-002 7P
Pancreatic Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Evomela
Pancreatic Neoplasm
General Oncology, Inc.
P1
C
(36)
ft536
Pancreatic Neoplasm
Fate Therapeutics
P1
C
(36)
gh21
Pancreatic Neoplasm
Suzhou Genhouse Bio Co., Ltd.
P1
C
(36)
Glofitamab
Pancreatic Cancer
German Cancer Research Center
P1
C
(36)
Hbi-2376
Pancreatic Neoplasm
HUYABIO International, LLC.
P1
C
(36)
hs-10502
Pancreatic Neoplasm
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(36)
hu5B1-TCO
Pancreatic Neoplasm
Memorial Sloan Kettering Cancer Center
P1
C
(36)
Icovamenib
Pancreatic Neoplasm
Biomea Fusion Inc.
P1
C
(36)
ide892
Pancreatic Neoplasm
IDEAYA Biosciences
P1
C
(36)
Idov-Immune
Pancreatic Neoplasm
ViroMissile, Inc.
P1
C
(36)
ik-595
Pancreatic Neoplasm
Ikena Oncology
P1
C
(36)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION)
Pancreatic Neoplasm
NYU Langone Health
P1
C
(36)
Iodixanol
Pancreatic Neoplasm
Brian Henick, MD
P1
C
(36)
ix001 tcr-t
Pancreatic Neoplasm
Sun Yat-sen University
P1
C
(36)
ix001 tcr-t cells
Pancreatic Neoplasm
Shanghai Pudong Hospital
P1
C
(36)
Kras Peptide Vaccine
Pancreatic Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
P1
C
(36)
lb1908
Pancreatic Neoplasm
Legend Biotech USA Inc
P1
C
(36)
ly4052031
Pancreatic Neoplasm
Eli Lilly and Company
P1
C
(36)
ly4101174
Pancreatic Neoplasm
Eli Lilly and Company
P1
C
(36)
MAT2A-IN-9
Pancreatic Neoplasm
IDEAYA Biosciences
P1
C
(36)
Mem-288 Intratumoral
Pancreatic Neoplasm
Memgen, Inc.
P1
C
(36)
Mitazalimab
Pancreatic Neoplasm
University of California, San Diego
P1
C
(36)
Showing 251 to 275 of 368 assets
Previous
Page 11 of 15
Next
